Publicaciones en las que colabora con Patricia Palau Sampio (21)

2024

  1. Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 206-214

2023

  1. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 511-518

2022

  1. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

    Scientific Reports, Vol. 12, Núm. 1

  2. Iron deficiency testing in acute heart failure. Much to do

    REC: CardioClinics, Vol. 57, Núm. 4, pp. 296-299

  3. Long-Term Prognostic Impact of Estimated Glomerular Filtration Rate on Admission in Patients Hospitalized for Acute Heart Failure

    CardioRenal Medicine, Vol. 12, Núm. 4, pp. 179-188

  4. Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure

    Revista Espanola de Cardiologia, Vol. 75, Núm. 4, pp. 316-324

  5. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure

    European Journal of Internal Medicine, Vol. 95, pp. 67-73

  6. Sex-Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum

    Journal of the American Heart Association, Vol. 11, Núm. 1

  7. Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial

    Journal of the American Heart Association, Vol. 11, Núm. 7, pp. e022214

2021

  1. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

    European Journal of Heart Failure, Vol. 23, Núm. 9, pp. 1445-1457

  2. Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure

    European Journal of Internal Medicine, Vol. 92, pp. 94-99

  3. Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure

    Medicina Clinica, Vol. 156, Núm. 12, pp. 589-594

  4. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

    Journal of the American College of Cardiology, Vol. 78, Núm. 21, pp. 2042-2056

  5. Iron deficiency and short-term adverse events in patients with decompensated heart failure

    Clinical Research in Cardiology, Vol. 110, Núm. 8, pp. 1292-1298

2020

  1. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

    American Journal of Medicine, Vol. 133, Núm. 3, pp. 370-380.e4

  2. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial

    Journal of the American Heart Association, Vol. 9, Núm. 4

  3. Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 4222-4230

2018

  1. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design

    Clinical Cardiology, Vol. 41, Núm. 6, pp. 729-735

2017

  1. Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

    Revista Espanola de Cardiologia, Vol. 70, Núm. 12, pp. 1067-1073

2016

  1. Carbohydrate Antigen-125–Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study

    JACC: Heart Failure, Vol. 4, Núm. 11, pp. 833-843